Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Aquestive Therapeutics, Inc. (AQST) had 12 insider filings in the last 90 days, with the most recent on 2026-08-18. The full record for AQST runs to 52 Form 4 filings, the earliest from 2024-11-27. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying AQST stock?
No insider purchases of AQST were filed in the last 90 days.
How many insiders are selling AQST stock?
5 insider sales of AQST were filed in the last 90 days, totaling $437K.
Where can I see AQST SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page tracks AQST Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow AQST insider buys?
Create a free InsiderAlpha account and press Watch on this page to add AQST to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
Daniel Barber - OfficerOpen-market sale$107K
